Merck, 14-736M, TAO2 Protein, active, 10 µg

General description
N-terminal 6His-tagged, recombinant, TAO2. TAO2 is a mitogen-activated protein kinase kinase kinase (MAP3K) that doubly phosphorylates and activates the MAP kinase kinases (MAP2Ks) MEK3 and MEK6.
Product Source: expressed in Sf21 cells
Application
Research Category
Metabolism
Research Sub Category
Cardiovascular Disease

Metabolic Disorders
Biochem/physiol Actions
Protein Target: TAO2
Target Sub-Family: STE
Physical form
10 μg of enzyme in 100 μL of 50 mM Tris/HCl pH7.5, 300 mM NaCl, 0.1 mM EGTA, 0.03% Brij 35, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.
Ni²⁺/NTA-agarose
Preparation Note
Stable for 6 months at -70°C from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap.
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.
Analysis Note
Routinely evaluated by phosphorylation of 0.8 mg/ml myelin basic protein (MBP). Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μg of TAO2.
Other Notes
Specific Activity: where one unit of TOA2 activity is defined as 1 nmol phosphate incorporated into 0.8 mg/mL myelin basic per minute at 30°C with a final ATP concentration of 100 μM.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.